Despite soaring demand for GLP-1s, many eligible patients are unable… | HappeningNow.news

Health · 6 views

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss

In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight…

Source Summary Published 54m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 6 Community interest
Brief read Under 1 min brief 78 words

Summary

In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).

Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page